glp-1 side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists What to Expect After First
Description
Should a GLP-1 (Glucagon-like peptide-1) receptor agonist, such as semaglutide (generic name) or tirzepatide (generic name), be continued or discontinued in a patient who has achieved a BMI reduction from 30 to 22?

Impaired glucose tolerance and impaired fasting glucose

Conclusions Small molecule GLP-1 receptor agonists represent an innovative advancement in the management of T2DM and obesity

J Gastroenterol Hepatol 33(1):232239

Mass spectra analysis reveals molecular weights and fragmentation patterns, enabling detection of impurities like oxidation products and deamidated peptides
This type of big data research will generate lots of statistical associations, some of which will be spurious